Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: A population-based matched case-control study

JAMA Internal Medicine

Volumn 173, Issue 7, 2013, Pages 534-539

  Singh, Sonal ^a,b   Chang, Hsien Yen ^b   Richards, Thomas M ^b   Weiner, Jonathan P ^b   Clark, Jeanne M ^a   Segal, Jodi B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; METFORMIN; SITAGLIPTIN;

ACUTE PANCREATITIS; ADULT; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ARTICLE; BILE DUCT CANCER; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; GALLSTONE; HOSPITALIZATION; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS CANCER; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; SEX DIFFERENCE; TOBACCO DEPENDENCE; TREATMENT DURATION; UNITED STATES;

ACUTE DISEASE; ADOLESCENT; ADULT; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PANCREATITIS; PEPTIDES; PYRAZINES; RISK FACTORS; TRIAZOLES; VENOMS;

EID: 84876063836     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.2720     Document Type: Article

References (22)

1. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194-206.
2. Butler PC, Dry S, Elashoff R. GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care. 2010;33(2):453-455.
3. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010;33(2):428-433.
4. Nachnani JS, Bulchandani DG, Nookala A, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia. 2010;53(1):153-159.
5. Matveyenko AV, Dry S, Cox HI, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes. 2009;58(7):1604-1615.
6. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the KrasG12D mouse model. Diabetes. 2012;61(5):1250-1262.
7. Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl JMed. 2008;358(18):1970-1972.
8. US Food and Drug Administration. Sitagliptin (marketed as Januvia and Janumet): reports of acute pancreatitis. http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183800.htm. Accessed June 30, 2012.
9. US Food and Drug Administration. Information of healthcare professionals: exenatide (marketed as Byetta): 8/2008 update. http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm. Accessed June 30, 2012.
10. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150-156.
11. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33(11):2349-2354.
12. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25(4):1019-1027.
13. Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab. 2011;13(6):559-566.
14. Herrera V, Ronald Aubert R, Tully L, et al. Pancreatitis in patients treated with exenatide or sitagliptin [abstract 10-LB]. Abstract presented at: 69th Scientific Session of the American Diabetes Association; June 6, 2009; New Orleans, LA.
15. Williams-Herman D, Round E, Swern AS, et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord. 2008;8:14. doi:10.1186/1472-6823-8-14.
16. Singh S, Loke YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials. 2012;13:138. doi:10.1186/1745-6215-13-138.
17. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32(5):834-838.
18. Moores K, Gilchrist B, Carnahan R, Abrams T. A systematic review of validated methods for identifying pancreatitis using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):194-202.
19. Young BA, Lin E, Von Korff M, et al. Diabetes Complications Severity Index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008;14(1):15-23.
20. Health Services Research and Development Center. The Johns Hopkins ACG Case-Mix System Reference Manual, Version 7.0. Baltimore, MD: Johns Hopkins University Bloomberg School of Public Health; 2005.
21. Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Predicting costs with diabetes complications severity index in claims data. Am J Manag Care. 2012;18(4):213-219.
22. Lando HM, Alattar M, Dua AP. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase- 4 inhibitors in the outpatient setting. Endocr Pract. 2012;18(4):472-477.